| NCT ID | NCT00478712 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Hirschsprung Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2001-01 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2001-01 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hirschsprung disease is a genetic condition caused by lack of nerve cells in varying lengths of the intestines. This study will investigate the complex genetic basis of the disease, which involves multiple interacting genetic factors.
Eligibility Criteria
Inclusion Criteria: \- Individuals with Hirschsprung disease and their first degree relatives (any segment length of disease, with or without other congenital anomalies or health problems, single or multiple affected individuals in family) Exclusion Criteria: * Unable or unwilling to provide sample for genetic studies * Individual, parent, or guardian unable to comprehend and provide informed consent
Contact & Investigator
Aravinda Chakravarti, PhD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT00478712 clinical trial?
This trial is open to participants of all sexes, aged 1 Week or older, up to 100 Years, studying Hirschsprung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00478712 currently recruiting?
Yes, NCT00478712 is actively recruiting participants. Contact the research team at jenna.pucel@nyulangone.org for enrollment information.
Where is the NCT00478712 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT00478712 clinical trial?
NCT00478712 is sponsored by NYU Langone Health. The principal investigator is Aravinda Chakravarti, PhD at NYU Langone Health. The trial plans to enroll 3,000 participants.